PYXS
Pyxis Oncology Inc

2,465
Mkt Cap
$284.55M
Volume
777,993.00
52W High
$4.86
52W Low
$0.8332
PE Ratio
-2.87
PYXS Fundamentals
Price
$4.53
Prev Close
$4.57
Open
$4.67
50D MA
$3.19
Beta
1.30
Avg. Volume
820,699.30
EPS (Annual)
-$1.32
P/B
4.13
Rev/Employee
$366,954.54
Loading...
Loading...
News
all
press releases
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Recommendation of "Hold" by Brokerages
Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) has earned an average recommendation of "Hold" from the seven brokerages that are covering the stock, MarketBeat reports. One research analyst has...
MarketBeat·7d ago
News Placeholder
More News
News Placeholder
HC Wainwright Boosts Earnings Estimates for Pyxis Oncology
Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) - Equities researchers at HC Wainwright lifted their FY2029 earnings per share estimates for shares of Pyxis Oncology in a research note issued to...
MarketBeat·8d ago
News Placeholder
Brokers Issue Forecasts for Pyxis Oncology FY2027 Earnings
Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) - Analysts at William Blair issued their FY2027 earnings estimates for Pyxis Oncology in a report released on Tuesday, November 4th. William Blair...
MarketBeat·13d ago
News Placeholder
Zacks Industry Outlook Highlights Akebia Therapeutics, Ironwood Pharmaceuticals, Pyxis Oncology, Cardiol Therapeutics and Plus Therapeutics
Small-cap biotech momentum surges as AKBA, IRWD, PYXS, CRDL, and PSTV gain on pipeline progress and sector recovery.
Zacks·1mo ago
News Placeholder
Pyxis Oncology (PYXS) Upgraded to Strong Buy: Here's What You Should Know
Pyxis Oncology (PYXS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·1mo ago
News Placeholder
5 Small Drug Stocks to Buy as the Industry Shows Some Recovery
Innovation is at its peak in the Zacks Medical-Drugs industry. AKBA, IRWD, PYXS, CRDL and PSTV may prove to be good additions to one's portfolio.
Zacks·1mo ago
News Placeholder
Should You Buy Pyxis Oncology, Inc. (PYXS) After Golden Cross?
Is it a good or bad thing when a stock experiences a golden cross technical event?
Zacks·2mo ago
News Placeholder
Investing in Oncology: 3 Cancer Stocks With Promising Pipelines
Relay Therapeutics, Pyxis Oncology and Allogene Therapeutics drive cancer innovation with pivotal trials and promising drug candidates.
Zacks·2mo ago
News Placeholder
Pyxis Oncology's Cancer Drug Platform Shows Potential, Analyst Sees Over 190% Upside
Stephens initiates coverage on Pyxis Oncology (PYXS), highlighting its promising ADC technology and a $13 price target, with upcoming clinical trial results. Latest Ratings for PYXS...
Benzinga·1y ago
News Placeholder
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Pyxis Oncology, Inc. (NASDAQ:PYXS)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Pyxis Oncology, Inc...
PR Newswire·1y ago

Latest PYXS News

View

Advertisement|Remove ads.

Advertisement|Remove ads.